{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:55:23Z","timestamp":1791489323599,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"publisher","award":["RP 2020-03"],"award-info":[{"award-number":["RP 2020-03"]}],"id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and aims<\/jats:title>\n            <jats:p>Alcohol-associated liver disease (ALD) with steatosis or steatohepatitis that could progress to liver cirrhosis is a common problem in chronic alcohol consumption. Pemafibrate is a novel, highly specific peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) modulator, which regulates the expression of the target genes related to lipid and glucose metabolism. Here, we evaluated the effect of pemafibrate to prevent ALD and steatosis in rats.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The animals were treated with liquid diet containing ethanol (36% of total calories) or an isocaloric carbohydrate diet for 4\u00a0weeks. Subsequently, both groups were fed with either 0.5% aqueous methylcellulose solution (MC) or MC containing 0.3\u00a0mg\/kg body weight of pemafibrate orally twice a day along with the liquid diet for another 4\u00a0weeks. A set of animals were sacrificed at the 4th week before the start of pemafibrate treatment and the remaining animals at the end of 8\u00a0weeks. Blood and liver samples were collected for biochemical and histopathological evaluations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Treatment with pemafibrate prevented inflammation and steatosis in the hepatic tissue. Furthermore, pemafibrate administration markedly increased hepatic NAD and NADH levels, reduced both serum and hepatic triglyceride levels, and upregulated the expression of molecules involved in lipid metabolism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results of the present study demonstrated that pemafibrate modulates target genes related to hepatic lipid metabolism and prevents deposition of fat globules in the liver during chronic alcohol feeding in rats. Therefore, pemafibrate could be used as a potent therapeutic agent to prevent steatosis and related adverse events in ALD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10020-025-01210-9","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:35:29Z","timestamp":1745307329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pemafibrate modulates peroxisome proliferator-activated receptor alpha and prevents alcohol-associated liver disease in rats"],"prefix":"10.1186","volume":"31","author":[{"given":"Takashi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7884","authenticated-orcid":false,"given":"Joseph","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Tsuchishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"1","key":"1210_CR1","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41598-023-29607-8","volume":"13","author":"D Azouaoui","year":"2023","unstructured":"Azouaoui D, Choini\u00e8re MR, Khan M, Sayfi S, Jaffer S, Yousef S, Patten DA, Green AE, Menzies KJ. Meta-analysis of NAD(P)(H) quantification results exhibits variability across mammalian tissues. Sci Rep. 2023;13(1):2464. https:\/\/doi.org\/10.1038\/s41598-023-29607-8.","journal-title":"Sci Rep"},{"issue":"5","key":"1210_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751\u20139. https:\/\/doi.org\/10.1002\/hep.25889.","journal-title":"Hepatology"},{"issue":"16","key":"1210_CR3","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA. Pemafibrate: first global approval. Drugs. 2017;77(16):1805\u201310. https:\/\/doi.org\/10.1007\/s40265-017-0818-x.","journal-title":"Drugs"},{"issue":"5","key":"1210_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, De Bosscher K. Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation. Endocr Rev. 2018;39(5):760\u2013802. https:\/\/doi.org\/10.1210\/er.2018-00064.","journal-title":"Endocr Rev"},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.freeradbiomed.2021.04.018","volume":"169","author":"X Chen","year":"2021","unstructured":"Chen X, Xu Y, Denning KL, Grigore A, Lu Y. PPAR\u03b1 agonist WY-14,643 enhances ethanol metabolism in mice: role of catalase. Free Radic Biol Med. 2021;169:283\u201393. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.04.018.","journal-title":"Free Radic Biol Med"},{"key":"1210_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154338","volume":"114","author":"A Christofides","year":"2021","unstructured":"Christofides A, Konstantinidou E, Jani C, Boussiotis VA. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism. 2021;114: 154338. https:\/\/doi.org\/10.1016\/j.metabol.2020.154338.","journal-title":"Metabolism"},{"issue":"30","key":"1210_CR7","doi-asserted-by":"publisher","first-page":"27997","DOI":"10.1074\/jbc.M302140200","volume":"278","author":"M Fischer","year":"2003","unstructured":"Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist treatment reverses PPAR-alpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem. 2003;278(30):27997\u20138004. https:\/\/doi.org\/10.1074\/jbc.M302140200.","journal-title":"J Biol Chem"},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1475-2840-12-82","volume":"12","author":"JC Fruchart","year":"2013","unstructured":"Fruchart JC. Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists. Cardiovasc Diabetol. 2013;12:82. https:\/\/doi.org\/10.1186\/1475-2840-12-82.","journal-title":"Cardiovasc Diabetol"},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2891-13-17","volume":"13","author":"B Grygiel-G\u00f3rniak","year":"2014","unstructured":"Grygiel-G\u00f3rniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review. Nutr J. 2014;13:17. https:\/\/doi.org\/10.1186\/1475-2891-13-17.","journal-title":"Nutr J"},{"key":"1210_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102792","volume":"64","author":"PS Harris","year":"2023","unstructured":"Harris PS, McGinnis CD, Michel CR, Marentette JO, Reisdorph R, Roede JR, Fritz KS. Click chemistry-based thiol redox proteomics reveals significant cysteine reduction induced by chronic ethanol consumption. Redox Biol. 2023;64: 102792. https:\/\/doi.org\/10.1016\/j.redox.2023.102792.","journal-title":"Redox Biol"},{"issue":"7","key":"1210_CR11","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1053\/gast.2002.33613","volume":"122","author":"JB Hoek","year":"2002","unstructured":"Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology. 2002;122(7):2049\u201363. https:\/\/doi.org\/10.1053\/gast.2002.33613.","journal-title":"Gastroenterology"},{"issue":"1","key":"1210_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12(1):173\u201384. https:\/\/doi.org\/10.1016\/j.jacl.2017.10.006.","journal-title":"J Clin Lipidol"},{"key":"1210_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12864-015-1969-3","volume":"16","author":"AW Janssen","year":"2015","unstructured":"Janssen AW, Betzel B, Stoopen G, Berends FJ, Janssen IM, Peijnenburg AA, Kersten S. The impact of PPAR\u03b1 activation on whole genome gene expression in human precision cut liver slices. BMC Genomics. 2015;16:760. https:\/\/doi.org\/10.1186\/s12864-015-1969-3.","journal-title":"BMC Genomics"},{"issue":"4","key":"1210_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1194\/jlr.R119000547","volume":"61","author":"S Jeon","year":"2020","unstructured":"Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res. 2020;61(4):470\u20139. https:\/\/doi.org\/10.1194\/jlr.R119000547.","journal-title":"J Lipid Res"},{"issue":"4","key":"1210_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3390\/ijms19040949","volume":"19","author":"S Lamichane","year":"2018","unstructured":"Lamichane S, Dahal Lamichane B, Kwon SM. Pivotal roles of peroxisome proliferator-activated receptors (PPARs) and their signal cascade for cellular and whole-body energy homeostasis. Int J Mol Sci. 2018;19(4):949. https:\/\/doi.org\/10.3390\/ijms19040949.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1210_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2004.10.005","volume":"9","author":"CS Lieber","year":"2005","unstructured":"Lieber CS. Metabolism of alcohol. Clin Liver Dis. 2005;9(1):1\u201335. https:\/\/doi.org\/10.1016\/j.cld.2004.10.005.","journal-title":"Clin Liver Dis"},{"issue":"4","key":"1210_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/ajcn\/23.4.474","volume":"23","author":"CS Lieber","year":"1970","unstructured":"Lieber CS, DeCarli LM. Quantitative relationship between amount of dietary fat and severity of alcoholic fatty liver. Am J Clin Nutr. 1970;23(4):474\u20138. https:\/\/doi.org\/10.1093\/ajcn\/23.4.474.","journal-title":"Am J Clin Nutr"},{"key":"1210_CR18","doi-asserted-by":"publisher","first-page":"1074911","DOI":"10.3389\/fendo.2022.1074911","volume":"13","author":"Y Lin","year":"2022","unstructured":"Lin Y, Wang Y, Li PF. PPAR\u03b1: an emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. Front Endocrinol (Lausanne). 2022;13:1074911. https:\/\/doi.org\/10.3389\/fendo.2022.1074911.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1210_CR19","doi-asserted-by":"publisher","first-page":"G483","DOI":"10.1152\/ajpgi.00281.2023","volume":"326","author":"Y Lu","year":"2024","unstructured":"Lu Y, George J. Interaction between fatty acid oxidation and ethanol metabolism in liver. Am J Physiol Gastrointest Liver Physiol. 2024;326(5):G483\u201394. https:\/\/doi.org\/10.1152\/ajpgi.00281.2023.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1210_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176345","volume":"134","author":"B Mackowiak","year":"2024","unstructured":"Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Invest. 2024;134(3): e176345. https:\/\/doi.org\/10.1172\/JCI176345.","journal-title":"J Clin Invest"},{"key":"1210_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","volume":"5","author":"S Mitra","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. https:\/\/doi.org\/10.21037\/tgh.2019.09.08.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"3","key":"1210_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1124\/jpet.108.143271","volume":"327","author":"R Mukherjee","year":"2008","unstructured":"Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O\u2019Malley KM, Zhang L, Li J, Shi Y, Kennedy LJ, Blanar M, Cheng PT, Tino J, Srivastava RA. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther. 2008;327(3):716\u201326. https:\/\/doi.org\/10.1124\/jpet.108.143271.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1210_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/hep.20399","volume":"40","author":"T Nakajima","year":"2004","unstructured":"Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology. 2004;40(4):972\u201380. https:\/\/doi.org\/10.1002\/hep.20399.","journal-title":"Hepatology"},{"issue":"10","key":"1210_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","volume":"54","author":"A Nakajima","year":"2021","unstructured":"Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54(10):1263\u201377. https:\/\/doi.org\/10.1111\/apt.16596.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1210_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101499","volume":"29","author":"GEC Narro","year":"2024","unstructured":"Narro GEC, D\u00edaz LA, Ortega EK, Gar\u00edn MFB, Reyes EC, Delfin PSM, Arab JP, Bataller R. Alcohol-related liver disease: a global perspective. Ann Hepatol. 2024;29(5): 101499. https:\/\/doi.org\/10.1016\/j.aohep.2024.101499.","journal-title":"Ann Hepatol"},{"issue":"2","key":"1210_CR26","first-page":"147","volume":"38","author":"NA Osna","year":"2017","unstructured":"Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38(2):147\u201361.","journal-title":"Alcohol Res"},{"issue":"3","key":"1210_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039.","journal-title":"J Hepatol"},{"key":"1210_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tgh-20-125","volume":"6","author":"P Prasun","year":"2021","unstructured":"Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol. 2021;6:4. https:\/\/doi.org\/10.21037\/tgh-20-125.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"12","key":"1210_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18491","volume":"28","author":"T Saito","year":"2024","unstructured":"Saito T, Tsuchishima M, Tsutsumi M, George J. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis. J Cell Mol Med. 2024;28(12): e18491. https:\/\/doi.org\/10.1111\/jcmm.18491.","journal-title":"J Cell Mol Med"},{"key":"1210_CR30","doi-asserted-by":"publisher","first-page":"34394","DOI":"10.1038\/srep34394","volume":"6","author":"MR Sawaya","year":"2016","unstructured":"Sawaya MR, Verma M, Balendiran V, Rath NP, Cascio D, Balendiran GK. Characterization of WY 14,643 and its complex with aldose reductase. Sci Rep. 2016;6:34394. https:\/\/doi.org\/10.1038\/srep34394.","journal-title":"Sci Rep"},{"issue":"4","key":"1210_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/2231-4040.90879","volume":"2","author":"S Tyagi","year":"2011","unstructured":"Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2(4):236\u2013320. https:\/\/doi.org\/10.4103\/2231-4040.90879.","journal-title":"J Adv Pharm Technol Res"},{"key":"1210_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbrc.2022.04.132","volume":"613","author":"Y Xu","year":"2022","unstructured":"Xu Y, Denning KL, Lu Y. PPAR\u03b1 agonist WY-14,643 induces the PLA2\/COX-2\/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice. Biochem Biophys Res Commun. 2022;613:47\u201352. https:\/\/doi.org\/10.1016\/j.bbrc.2022.04.132.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1210_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22(1):5. https:\/\/doi.org\/10.1007\/s11883-020-0823-5.","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"1210_CR34","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1124\/dmd.122.000908","volume":"50","author":"J Yang","year":"2022","unstructured":"Yang J, Fan S, Zhang Y, Huang M, Gao Y, Bi H. Chronic treatment with WY-14643 induces tumorigenesis and triglyceride accumulation in mouse livers. Drug Metab Dispos. 2022;50(12):1464\u201371. https:\/\/doi.org\/10.1124\/dmd.122.000908.","journal-title":"Drug Metab Dispos"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01210-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:35:30Z","timestamp":1745307330000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01210-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01210-9","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were carried out as per the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 86-23, revised 1996). The animal experimental protocol was approved by the Animal Care and Use Committee of Kanazawa Medical University on the Ethics of use and care of experimental animals (#2022-29).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}